Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13696803 | 0.97 | USP30 (0.44) | USP30JAK2JAK1CYP2D6SLC6A2 | |
| SCHEMBL13696800 | 0.88 | USP30 (0.46) | USP30JAK2JAK1SLC6A2SLC6A4 | |
| SCHEMBL4121587 | 0.87 | SLC6A2 (0.44) | USP30CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13696792 | 0.86 | SLC6A2 (0.53) | USP30JAK2JAK1CYP2D6SLC6A2 | |
| SCHEMBL13696791 | 0.86 | USP30 (0.47) | USP30JAK2JAK1CYP2D6SLC6A2 | |
| SCHEMBL13696801 | 0.85 | SLC6A2 (0.58) | USP30JAK2JAK1CYP2D6SLC6A2 | |
| SCHEMBL4106291 | 0.84 | SLC6A2 (0.45) | USP30CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5201833 | 0.82 | USP30 (0.45) | USP30JAK2JAK1SLC6A2SLC6A4 | |
| SCHEMBL13696806 | 0.82 | USP30 (0.48) | USP30SLC6A2SLC6A4SLC6A3GPR119 | |
| SCHEMBL13696774 | 0.76 | SLC6A2 (0.57) | USP30JAK2JAK1CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239928-A1 | N-Pyrrolidin-3YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | AOC3, AOC2, TPH2 | USP30 3226/4885JAK2 3470/4885JAK1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.